RussianPatents.com

Clatrate complex of cyclodextrine or arabinogalactane with 9-phenyl-symm-octahydroselenoxantene, its production method (versions), pharmaceutical composition and medication. RU patent 2451680.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a new clatrate complex of α-, β-, γ- or hydroxipropyl-β-cyclodextrine or arabinogalactane with 9-phenyl-symm-octahydroselenoxantene with formula (1) possibly - in α-crystalline form. The weight ratio of 9-phenyl-symm-octahydroselenoxantene to Cyclodextrine is from 1:3 to 1:30 or the weight ratio of 9-phenyl-symm-octahydroselenoxantene to arabinogalactane is from 1:10 to 1:20. Additionally proposed are a liquid phase method of the complex production, a solid phase method of the complex production, a pharmaceutical composition and a medication.

EFFECT: invention allows to improve water solubility and bioavailability and to reduce the toxic action of symm-octahydroselenoxantene.

16 cl, 14 dwg, 3 tbl, 1 ex

IPC classes for russian patent Clatrate complex of cyclodextrine or arabinogalactane with 9-phenyl-symm-octahydroselenoxantene, its production method (versions), pharmaceutical composition and medication. RU patent 2451680. (RU 2451680):

C08B37 - Preparation of polysaccharides not provided for in groups ; C08B0001000000-C08B0035000000; Derivatives thereof (cellulose D21)

C07D345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms

A61K47/40 - Cyclodextrins; Derivatives thereof

A61K47/36 - Polysaccharides; Derivatives thereof

Another patents in same IPC classes:

Method of determining antibacterial activity of chitosan / 2450022
Disclosed is a method of determining antibacterial properties of chitosan by estimating its minimum bacteriostatic and/or bactericidal concentration. Complex buffer solutions based on three organic acids MES, ACES and TES with different pH values are prepared. The ready buffer solutions are poured into a vessel. Double dilutions of chitosan are then prepared in vessels with the buffer solutions. Aliquots of a bacterial suspension in a fluid medium are added to the chitosan solutions in the buffer. The solutions are incubated for 24 hours at temperature which is optimum for bacterial growth. The minimum bacteriostatic and/or minimum bactericidal concentration of chitosan is then determined after incubation by determining growth of the culture or a drop in the number of living cells, respectively.

Kefiran production method / 2450021
Kefiran production method involves kefiran extraction from kefir fungi in boiling water, the produced solution cooling, kefiran precipitation with an equivalent quantity of ethanol, the solution maintenance, the product drying, extraction is performed (while stirring) in boiling water at a ratio of kefir fungi to water equal to approximately 1:10 during 5-10 minutes till homogeneous mass production. In the process of cooling one adds a proteolytic enzyme and maintains the product at a temperature and pH optimal for the proteolytic enzyme used during no less than 1 hour; the extract cooled to 20°C is filtered through a fine filter; after ethanol precipitation the sediment is filtered, washed with distilled water and repeatedly filtered several times.

Clathrate complexes of beta-cyclodextrin with 1-{[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-h-indol-3-yl]carbonyl}-4-benzylpiperazine, having antiviral activity, synthesis and use thereof / 2448120
Invention relates to a novel clathrate complex of β-cyclodextrin with 1-{[6-bromo-1-methyl-5-methoxy-2-phehylthiomethyl-1-H-indol-3-yl]carbonyl}-4-benzylpiperazine of formula : with molar ratio 1-{[6-bromo-1-methyl-5-methoxy-2-phehylthiomethyl-1-H-indol-3-yl]carbonyl}-4-benzylpiperazine: β-cyclodextrin from 1:1 to 1:10, synthesis method and use thereof as an antiviral agent for treating influenza. The disclosed method involves mixing solutions of β-cyclodextrin and 1-{[6-bromo-1-methyl-5-methoxy-2-phehylthiomethyl-1-H-indol-3-yl]carbonyl}-4-benzylpiperazine in molar ratio from 1:1 to 1:10 while stirring and heating to temperature not higher than 70°C and then maintaining said conditions until a homogeneous solution is obtained and extraction of the obtained complex.

Method for production of polysaccharides of coniferous trees greens / 2448119
Method envisages milling coniferous trees greens. Then one extracts the tree greens with ethyl acetate and chloroform. Then remains are extracted in three stages: with distilled water, with water acidified with hydrochloric acid, with water solution of potassium hydroxide. Then one proceeds with concentration and settlement with ethyl alcohol. Then the sediment is centrifuged, dissolved in water and dialysed against distilled water. One performs lyophilic drying of the target product.

Method of producing water-soluble forms of aminomethyl terpenophenols / 2448085
Invention relates to a novel method of producing water-soluble forms of aminomethyl terpenophenols through a salt formation reaction of amines selected from a group of aminomethyl terpenophenols in 70% aqueous solution of an aliphatic alcohol, such as methanol, ethanol, propanol, isopropanol, or in a heterogeneous reaction medium consisting of water and a water-immiscible solvent, such as toluene, petroleum ether, diethyl ether, heated to temperature 30-70°C, with carboxyl-containing polysaccharides from a group of pectins, sulphated pectin derivatives, sulphated carboxymethylcellulose derivatives with aminomethyl terpenophenol content of 0.05-0.3 mol per free carboxyl group of polysaccharide while stirring for the process time of 60-240 minutes at temperature 15-25°C, with extraction of the obtained product.

Method of producing high-purity arabinogalactan / 2447086
Invention relates to methods of producing arabinogalactan. The method involves aqueous extraction of arabinogalactan from resin-free larchwood while heating. The obtained extract is concentrated and subjected to ultrafiltration. Ultrafiltration is carried out using coarse-pored cellulose acetate membranes UAM-500P. The obtained concentrate is treated with aqueous solution of a cationic flocculant. The clarified concentrated is treated with aqueous hydrogen peroxide solution in amount of 0.1-0.5 mol/l concentrate in the presence of a complexing agent in amount of 0.12-5.0 mmol/l. The ready product is extracted by spray drying.

Method for preparing boron-containing hyaluronic acid / 2445978
Invention refers to a method for preparing sodium salt of hyaluronic acid modified by boron compounds with no fluid medium added. The method consists in the fact that powdered sodium salt of hyaluronic acid together with a modifying agent and mixed modifying agents is pre-homogenised in a mixer at temperature ranging within 20° to 50°C; thereafter the prepared homogenous powder mixture is simultaneously exposed to pressure and shearing deformation in a mechanochemical reactor at temperature ranging within 20° to 50°C and pressure 5-1000 MPa.

Method of purifying non-protein fasciola antigens / 2445321
Method involves fractionation of a fasciola protein extract using chromatographic techniques. The pool of fractions in which non-protein antigens have been detected is treated with trichloroacetic acid. High pressure chromatography on an HR 10/30 column with superose 6 in an FPLC chromatographic system is used.

Method for producing chitosan oligomers / 2445101
Invention refers to medicine, more specifically to producing chitosan oligomers possessing biological activity and applicable in food industry and medicine. In a method for producing chitosan oligomers, a chitosan solution is taken in the concentration of 0.025-0.075% (weight/volume) and exposed to low-frequency ultrasound of the intensity of 92-460 Wt/cm2 for 5-30 minutes.

Thickening composition with improved viscosity development / 2444204
Invention relates to a composition for thickening containing a composition. The composition is characterised by content of xanthum gum having, per 100 weight parts thereof, 0.5 - 10 weight parts of a metal salt bonded to the xanthum gum powder surface by way of spraying the metal salt solution onto xanthum gum and subsequent fluid-bed drying. The thickening composition is suitable for application in beverages, gravies, sauces, soups, mousses and jellies.

Method for synthesis of endo-, exo-tetracyclo[4.5.1.0<sup>2,6</sup>.0<sup>8,11</sup>]dodec-3(4)-ene-9-spiro-1'-(3'-selenium)cyclopentanes

Method for synthesis of endo-, exo-tetracyclo[4.5.1.0^2,6.0^8,11]dodec-3(4)-ene-9-spiro-1'-(3'-selenium)cyclopentanes / 2404177
Method for synthesis of endo-, exo-tetracyclo- [4.5.1.02.6.08.11]dodec-3(4)-ene-9-spiro-1'-(3'-selenium)-cyclopentanes of general formula

1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15, 15a, 15b-tetradecahydrodicyclonone[b,d]selenophene synthesis method / 2401835
Present invention relates to a method for synthesis of 1,2,3,4,5,6,10,11,12,13,14,15,15a,15b-tetradecahydrodicyclonone[b,d]selenophene of general formula (1) . The method involves reaction of cyclonone-1,2-diene with ethylmagnesiumbromide (EtMgBr/ether) in the presence of Mg (powder) and a titanocene dichloride (Cp2TiCl2) catalyst taken in molar ratio cyclonone-1,2-diene : EtMgBr : Mg : Cp2TiCl2 = 20:(22-26):20:(1.0-1.4), preferably 20:24:20:1.2. The reaction takes place in an argon atmosphere at room temperature (20-22°C) and atmospheric pressure for 6-8 hours in diethyl ether, with subsequent addition of an amount of selenium (Se) which is equimolar to EtMgBr, benzene as a solvent and heating the reaction mass for 5 hours at temperature of approximately 40°C.

2-alkyl-5,6,7,8,9,10-hexahydro-4-cyclonone[b]selenophene synthesis method / 2389726
Invention relates to organic chemistry, specifically to a method of synthesising 2-alkyl-5,6,7,8,9,10-hexahydro-4H-cyclonone[b]selenophenes, which involves reaction of an equimolar mixture of cyclonone-1,2-diene and alka-1,2-diene (octa-1,2-diene, deca-1,2-diene, dodeca-1,2-diene) with EtMgBr in the presence of magnesium and a titanocene dichloride catalyst in an argon atmosphere at room temperature in diethyl ether for 2-4 hours with subsequent addition of Se in equimolar ratio to the EtMgBr amount and heating the reaction mass for 5 hours at approximately 40°C in benzene, and then for 1 hour at approximately 140°C.

Method for synthesis of 1,2,3,4,5,6,10,11,12,13,14,15,15a,15b-tetradecahydrodicyclonone [b, d] selenophene / 2383538
Method for synthesis of 1,2,3,4,5,6,10,11,12,13,14,15,15a,15b-tetradecahydrodicyclonone[b,d]selenophene with general formula (1):

2,4,6-tri-(p-methoxyphenyl)selenopyrilium showing antimicrobial activity / 2377240
It is shown that 2,4,6-tri-(p-methoxyphenyl)selenopyrilium in concentration 10-1 to 10-4 mg/ml taking action on E. coli, has suppressed bacteria reproduction 3.6 to 25.7%; while acting on growing culture K oxytoca, it has suppressed the growth 6.7 to 18.4 %; on growing culture P. aeruginosa, it has suppressed the growth 7.4 to 16.2 %.

Alpha-crystalline form of substituted selenoxanthenes and method of producing said form / 2374238
Invention relates to organic chemistry, particularly to the technology of producing selenoxanthenes and can be used in producing food additives, medicinal agents and cosmetic agents, which exhibit broad biological activity. An agent is described, which is an α-crystalline form of 9-phenyl-sym-octahydroselenoxanthene, which has antixodant, detoxication, immunomodulating, antiatherogenic, antisclerotic, anabolic, hypolipid action, and the corresponding structural formula with powder X-ray pattern obtained on Cu-K radiation sources with characteristic reflection indices expressed in degrees of the diffraction angle 2θ: 6.0 12.0 15.0 17.0 19.0 20.0 21.5, 21.7, 20.9 25.0 27.0 28.0 29.0 37.0 and melting temperature 96.8°C, as well as to a method of producing said agent, involving crystallisation of the corresponding 9-R-sym-hydroselenoxanthene from low-polar or non-polar solvent, preferably hexane, chloroform or isopropyl alcohol.

Method for preparation of 2,4,6-triarylselenium pyrylium chlorozincates / 2367658
Method for preparation of 2,4,6-triarylselenium pyrylium chlorozincates includes the interreaction of 1,3,5-aryl-substituted 1,5-diketones with hydrogen selenide obtained by dissolution of zinc selenide in the hydrogen chloride solution in diethyl ether. The reaction medium is obtained by reaction of phosphorus pentachloride with water in diethyl ether medium. The 2,4,6-triphenylselenium pyrylium chlorozincate, C23H17SeCl·0.5ZnCl2, 265-268°C, 57.5; 2,6-diphenyl-4-(n-methoxyphenyl)selenium pyrylium chlorozincate, C24H19SeO3Cl·0.5ZnCl2, 262-264°C, 60.5; 2,4,6-tri-(n-methoxyphenyl)selenium pyrylium chlorozincate C24H21SeO3Cl·0.5ZnCl2, 238-241°C, 71 are described.

Method for preparing selenopyrilium salts / 2276150
Invention relates to the improved method for preparing selenopyrilium salts by interaction of 1,5-diketones with hydrogen selenide that is prepared in dissolving zinc selenide in mixture of acetic acid, hydrogen bromide and diethyl ether. The reaction medium is prepared by addition of acetic acid bromoanhydride to mixture of diethyl ether and hydrogen bromide an aqueous solution. The following indices of compounds are given below as, name, empirical formula, melting point and the yield of the end product, %, respectively: 2,4,6-triphenylselenopyrilium bromozincate, C23H17SeZnBr3, 256-258°C, 75; 2,6-diphenyl-4-(p-methoxyphenyl)-selenopyrilium bromozincate, C24H19SeOZnBr3, 247-252°C, 71; 2,6-diphenyl-4-methylselenopyrilium bromozincate, C18H15SeZnBr3, 205-207°C, 68. All prepared salts have been converted to the corresponding perchlorates. Method provides excluding the use of gaseous hydrogen selenide.

Method of industrial obtaining preparation of alpha-fetoprotein / 2448727
Invention relates to medicine, namely to chemical-pharmaceutical industry and can be applied for industrial manufacturing injection preparation of alpha-fetoprotein (AFP). AFP is obtained from placental and(or) abortion human blood, by separation of ballast proteins from blood by centrifugation, filtration, carrying out chromatographic purifications, stabilisation by dextran, characterised by the fact that before centrifugation auxiliary substances - sodium chloride, triton X-100, chloroform and aprotinin are added.

Pharmaceutical composition and method for pulmonary administration thereof / 2445119
Invention relates to medicine, namely pharmacology. A pharmaceutical composition contains an active component selected from a group of pharmacologically active substances: having an effect on a central nervous system, peripheral neurotransmitter processes, cardiovascular system, coagulation system, neoplastic processes, metabolic processes, showing antibacterial activity, an excipient, cyclodextrin as a component ensuring high bioavailability, and a component modulating a duration of the pharmacologically active substance representing polymer. The pharmaceutical composition is presented in the form of a powder of particle size within 0.4 to 2 mcm. A method for administration of the pharmaceutical composition provides the pulmonary oral administration in the form of a dry or liquid aerosol with mass median aerodynamic diameter 0.8 to 2.0 mcm and degree of polydispersity 0.8 to 2.0.

Pharmaceutical composition for injections / 2443432
Pharmaceutical composition for injections contains a mixture of platinum complex of formula II and at least one cyclodextrin and/or at least one cyclodextrin derivative selected from a group comprising alpha-, beta- and gamma-cyclodextrins and their alkylated derivatives in mass ratios within 1:0.1 to 10:1 respectively, and optionally at least one pharmaceutically acceptable excipient. The composition is presented in the form of an aqueous solution prepared by adding an aqueous medium to cyclodextrin or its derivative that is followed by adding the platinum complex of formula ;